ppat.1010161.g002.tif (604.04 kB)
Animal models and immunobridging.
figure
posted on 2022-01-13, 18:23 authored by César Muñoz-Fontela, Lina Widerspick, Randy A. Albrecht, Martin Beer, Miles W. Carroll, Emmie de Wit, Michael S. Diamond, William E. Dowling, Simon G. P. Funnell, Adolfo García-Sastre, Nora M. Gerhards, Rineke de Jong, Vincent J. Munster, Johan Neyts, Stanley Perlman, Douglas S. Reed, Juergen A. Richt, Ximena Riveros-Balta, Chad J. Roy, Francisco J. Salguero, Michael Schotsaert, Lauren M. Schwartz, Robert A. Seder, Joaquim Segalés, Seshadri S. Vasan, Ana María Henao-Restrepo, Dan H. BarouchComparative and standardized studies in animal models such as those performed by WHO-COM scientists can help to extrapolate vaccine immunogenicity data across preclinical and clinical studies. Figure created with Biorender (Biorender.com). VAERD, vaccine-associated enhanced respiratory disease; VOC, variant of concern; WHO-COM, WHO COVID-19 Modeling group.
History
Usage metrics
Categories
Keywords
world health organizationinvestigate voc pathogenesisfacing new challengesevaluate voc virulenceanimal model researchcoronavirus disease 201919 demographic variablesparticular animal modelsanimal modelspreclinical modelsxlink ">vocs ).vaccine inequityvaccine correlatespostexposure therapieskey roleimmune escapeglobal response2 variants
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC